Candel Therapeutics (CADL) Non-Current Debt (2021 - 2023)
Historic Non-Current Debt for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to $14.3 million.
- Candel Therapeutics' Non-Current Debt fell 2873.97% to $14.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $14.3 million, marking a year-over-year decrease of 2873.97%. This contributed to the annual value of $20.2 million for FY2022, which is 350750.0% up from last year.
- Candel Therapeutics' Non-Current Debt amounted to $14.3 million in Q3 2023, which was down 2873.97% from $16.7 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Non-Current Debt ranged from a high of $20.2 million in Q4 2022 and a low of $560000.0 during Q4 2021
- In the last 3 years, Candel Therapeutics' Non-Current Debt had a median value of $19.5 million in 2022 and averaged $16.4 million.
- Per our database at Business Quant, Candel Therapeutics' Non-Current Debt surged by 350750.0% in 2022 and then plummeted by 2873.97% in 2023.
- Quarter analysis of 3 years shows Candel Therapeutics' Non-Current Debt stood at $560000.0 in 2021, then soared by 3507.5% to $20.2 million in 2022, then dropped by 29.02% to $14.3 million in 2023.
- Its Non-Current Debt stands at $14.3 million for Q3 2023, versus $16.7 million for Q2 2023 and $19.0 million for Q1 2023.